問卷

TPIDB > Principal Investigator

Principal Investigator



更新時間:2023-09-19

黃信偉Huang, Hsin-Wei
  • Co-Principal Investigator
  • Clinical Trial Experience (year) 8 years 1 個月
  • wf100320@tmu.edu.tw

篩選

List

2Cases

2025-11-01 - 2033-12-31

Phase III

Not yet recruiting
A phase III, open-label, randomized, multicenter, parallel-group trial evaluating the efficacy and safety of first-line trastuzumab deruxtecan combined with rilvegostomig or volrustomig versus pembrolizumab plus chemotherapy in locally advanced, unresectable, or metastatic HER2-overexpressing non-squamous NSCLC (DESTINY-Lung07).
  • Condition/Disease

    Locally advanced unresectable or metastatic HER2-overexpressing non-squamous non-small cell lung cancer

  • Test Drug

    Trastuzumab Deruxtecan(AZD4552 DS-8201A)

Participate Sites
9Sites

Recruiting9Sites

2017-07-01 - 2018-09-30

Phase II

A Phase 2, Double-blind, Randomized Controlled Study to Evaluate Immunogenicity and Safety of Intranasal Trivalent Influenza Virus Vaccine in Healthy Adult Volunteers
  • Condition/Disease

    Influenza Virus Vaccine

  • Test Drug

    AD07030

Participate Sites
5Sites

Terminated5Sites